ALSUntangled #67: rituximab

Li, Xiaoyan; Armon, Carmel; Barkhaus, Paul E.; Barnes, Benjamin; Benatar, Michael; Bertorini, Tulio E.; Bromberg, Mark B.; Carter, Gregory T.; Crayle, Jesse; Cudkowicz, Merit; Dimachkie, Mazen M.; Feldman, Eva L.; Glass, Jonathan D.; Goslinga, Jill; Heiman‐Patterson, Terry; Jhooty, Sartaj; Lichtenstein, Rachel G.; Lund, Isaac; McDermott, Christopher J.; Pattee, Gary L.; Pierce, Kaitlyn; Ratner, Dylan; Salmon, Kristiana; Wicks, Paul; Bedlack, Richard

doi:10.1080/21678421.2022.2122845

Cited by 2 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unpublished data from Lichtenstein's Lab suggested that reducing B cell counts by treating pre-symptomatic mSOD1 G93A mice with rituximab extended ALS mice survival. However, preclinical or clinical trials examining rituximab's efficacy in ALS are still lacking [85].…”

Section: Monoclonal Antibodiesmentioning

confidence: 99%

Can Some Anticancer Drugs Be Repurposed to Treat Amyotrophic Lateral Sclerosis? A Brief Narrative Review

Potenza,

Armida,

Popoli

2024

IJMS

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis (ALS) is a rare progressive motor neuron disease that, due to its high complexity, still lacks effective treatments. Development of a new drug is a highly costly and time-consuming process, and the repositioning of approved drugs can represent an efficient strategy to provide therapeutic opportunities. This is particularly true for rare diseases, which are characterised by small patient populations and therefore attract little commercial interest. Based on the overlap between the biological background of cancer and neurodegeneration, the repurposing of antineoplastic drugs for ALS has been suggested. The objective of this narrative review was to summarise the current experimental evidence on the use of approved anticancer drugs in ALS. Specifically, anticancer drugs belonging to different classes were found to act on mechanisms involved in the ALS pathogenesis, and some of them proved to exert beneficial effects in ALS models. However, additional studies are necessary to confirm the real therapeutic potential of anticancer drugs for repositioning in ALS treatment.

show abstract

Section: Monoclonal Antibodiesmentioning

confidence: 99%

Can Some Anticancer Drugs Be Repurposed to Treat Amyotrophic Lateral Sclerosis? A Brief Narrative Review

Potenza,

Armida,

Popoli

2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Interestingly, Pennati et al (2016) demonstrated that intravenous delivery of IL-10+ Bregs decreased myeloid-derived macrophages in the CNS of SOD1 G93A mice and did not significantly prolong survival, only modestly improving rotarod performance compared to the delivery of control splenocytes once a week for 3 weeks every month. In addition, a case report of a single patient who received Rituximab for treatment of ALS demonstrated no reported benefit ( Li et al, 2023 ).…”

Section: B Cells In Chronic and Neurodegenerative Pathologies Of The Cnsmentioning

confidence: 99%

Intruders or protectors – the multifaceted role of B cells in CNS disorders

Aspden,

Murphy,

Kashlan

et al. 2024

Front. Cell. Neurosci.

View full text Add to dashboard Cite

B lymphocytes are immune cells studied predominantly in the context of peripheral humoral immune responses against pathogens. Evidence has been accumulating in recent years on the diversity of immunomodulatory functions that B cells undertake, with particular relevance for pathologies of the central nervous system (CNS). This review summarizes current knowledge on B cell populations, localization, infiltration mechanisms, and function in the CNS and associated tissues. Acute and chronic neurodegenerative pathologies are examined in order to explore the complex, and sometimes conflicting, effects that B cells can have in each context, with implications for disease progression and treatment outcomes. Additional factors such as aging modulate the proportions and function of B cell subpopulations over time and are also discussed in the context of neuroinflammatory response and disease susceptibility. A better understanding of the multifactorial role of B cell populations in the CNS may ultimately lead to innovative therapeutic strategies for a variety of neurological conditions.

show abstract

ALSUntangled #67: rituximab

Cited by 2 publications

References 34 publications

Can Some Anticancer Drugs Be Repurposed to Treat Amyotrophic Lateral Sclerosis? A Brief Narrative Review

Can Some Anticancer Drugs Be Repurposed to Treat Amyotrophic Lateral Sclerosis? A Brief Narrative Review

Intruders or protectors – the multifaceted role of B cells in CNS disorders

Contact Info

Product

Resources

About